Adult Dosing
Male hypoganadism
- 5-20 mg PO qd; alt divided doses tid-qid
- In general, therapy is initiated with full therapeutic dose with subsequent adjustments
- Note: If priapism occurs, temporarily discontinue therapy and reinstitute at a lower dose
Males with delayed puberty
- 2.5-20 mg PO qd x 4-6 months
- Usual dose: 2.5-10 mg PO qd
Palliation of inoperable mammary cancer in women
- 10-40 mg/day PO divided tid-qid x 3 months or more depending upon patient response
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
See Supplemental Patient Information
- Fluoxymesterone may cause hypercalcemia in patients with breast cancer; discontinue treatment if this occurs
- Prolonged use of high doses can cause potentially life-threatening complications including hepatic adenomas, hepatocellular carcinoma, and peliosis hepatis
- Cholestatic hepatitis and jaundice may occur with fluoxymesterone, if such conditions occur consider discontinuation of therapy
- Geriatric patients are at an increased risk of developing prostatic hypertrophy and prostatic carcinoma
- Edema with or without congestive heart failure is a serious complication in patients with preexisting cardiac, renal, or hepatic disease
- Gynecomastia may occur and persist in patients being treated for hypogonadism
- Use cautiously in males with delayed puberty. Monitor effect on bone maturation by assessing bone age of the wrist and hand every 6 months. Fluoxymesterone may accelerate bone maturation without producing compensatory gain in linear growth
- Avoid use for enhancement of athletic performance
- Observe women for development of signs of virilization; discontinue use if such signs are noted
- Determine urine and serum calcium levels in women with disseminated breast carcinoma during the course of therapy
- Monitor Hg, HCT, LFTs, and periodic (every 6 months) X-ray examinations of bone age in prepubertal males
Cautions: Use cautiously in
- Hepatic impairment
- Hx of MI
- Hx of CAD
- Cardiovascular disorder
Supplemental Patient Information
- Instruct patient to report if there are frequent or persistent erections of the penis
- Advise male patients receiving androgens for delayed puberty to have bone development evaluated every six months
- Instruct female patients to report if hoarseness, acne, changes in menstrual periods or increased hair on the face occurs
- Advise patient to report if nausea, vomiting, changes in skin color or ankle swelling occurs
Pregnancy Category:X
Breastfeeding: Safety unknown; Not recommended during nursing
US Trade Name(s)
US Availability
fluoxymesterone (generic)
Androxy
Canadian Trade Name(s)
Canadian Availability
UK Trade Name(s)
UK Availability
Australian Trade Name(s)
Australian Availability